Hanmi Pharmaceutical Co., Ltd.

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2021🗂️ Report periods on file: 2021, 2019, 2018-01 to 2018-12

In its 2021 reporting, Hanmi Pharmaceutical Co., Ltd. disclosed greenhouse gas emissions of 59.5K tCO2e. By scope: Scope 1: 9.8K tCO2e; Scope 2: 49.7K tCO2e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
59.5K tCO2e
2021

📊 Emissions by Scope (2021)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).9.8K tCO2e
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.49.7K tCO2e

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
202159.5K tCO2e
201971.4K tCO2e/year (Scopes 1+2)
2018-01 to 2018-1249.2K tCO2e/year

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔭 Long-term

  • Carbon neutrality by 2050

🌱 ESG Focus Areas

R&D ManagementEthical ManagementTalent ManagementCustomer Satisfaction ManagementWin-win ManagementEHS (Environment, Health, Safety) Management

⚠️ Challenges & Risks +

  • Difficult management conditions persisted due to the rapid spread of COVID-19, including a highly uncertain and unstable economic environment and intensifying competition.
  • Global supply chain disruptions
  • Uncertainty of the global supply chain triggered by the COVID-19 pandemic

📋 Report Information

Reporting Period: 2021
Frameworks: GRI, SASB, ISO 26000
Assurance: Korea Standards Association